POISE -2: Clonidine does not reduce the risk of perioperative death or myocardial infarction in patients undergoing noncardiac surgery

There is some evidence that clonidine administered in small doses for short periods of time prior to noncardiac surgery would be able to prevent cardiac events.This study randomized 10010 patients over 45 years in 135 centers in 23 countries to clonidine or placebo. The primary end point of the study was the rate of death from any cause and nonfatal myocardial infarction at 30 days.At 30 days, the rate of death or infarction observed was 7.3 % in the clonidine group and 6.8 % in the placebo group (p = 0.29). Hypotension or bradycardia clinically important,were more frequent in the clonidine group, hypotension was an independent predictor of infarction (HR 1.37 , P < 0.001).

Conclusion

Clonidine does not reduce the risk of death or myocardial infarction in the perioperative period and should not be administered in patients undergoing noncardiac surgery in order to prevent events.

Article

1_daniel_sessler_slides
Daniel I. Sessler
2014-03-31

Original title: A Large International Trial Assessing the Effects of Clonidine on Major Arterial Events in Patients Having Noncardiac Surgery (POISE-2).

More articles by this author

MSC -HF Trial: Auto mesenchymal cell transplantation may improve ventricular function in patients with heart failure of ischemic cause

This study is a phase 2, randomized 2:1, double blind, and placebo-controlled included 59 patients with advanced heart failure of ischemic etiology undergoing autologous...

ZEUS Trial: Patients with increased risk of bleeding may benefit from eluting stents Zotarolimus

The use of drug-eluting stents versus bare metal stents is controversial in some clinical situations in patients at high risk of bleeding.This study randomized...

NEXT Trial: Biodegradable polymer stent (Nobori) was similar to the permanent polymer stents (Xience / Promus) at 2 years.

This multicenter work from Japanrandomized 3200 patients to receive biodegradable polymer biolimus eluting stent(Nobori) or everolimus-eluting stent with permanent polymer (Xience / Promus). The...

SIRS Trial: Methylprednisolone does not decrease mortality and increase the risk of stroke in patients undergoing cardiac surgery

Cardiac surgery with cardiopulmonary bypass results in an inflammatory response of the body that is usually associated with adverse outcome. The preventive use of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...